The present invention provides compositions and methods for the treatment of Amyotrophic lateral sclerosis (ALS). ALS is a lethal disease with varying rates of progression. Some patients can live decades, while others die within 3-5 years. Clinical features, demographics, or genetics do not fully explain the wide variation in ALS disease progression. However, ALS impacts the gut microbiome, and it is known that gut microbiome composition can impact neurological function. Introducing bacteria from the guts of individuals with slow disease progression to other individuals slows ALS progression, and presents a promising means of treating ALS.
Disclosed herein are drug delivery compositions that can control the release of an immunotherapy drug by balancing the amounts of different elastin-like polypeptides. An example composition includes a first elastin-like polypeptide, a second elastin-like polypeptide having an oligolysine domain, and a CpG oligodeoxynucleotide. Also disclosed herein are pharmaceutical compositions that include the composition, methods of treating a cancer, and methods of controlling the release of a CpG oligodeoxynucleotide.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 9/38 - Organic coatings containing proteins or derivatives thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
3.
ADVANCED ROBOTIC SYSTEMS FOR HIGH-THROUGHPUT MULTIFACETED PHAGE-ASSISTED CONTINUOUS EVOLUTION
The present disclosure relates to systems and methods for evolution of biomolecules, and more particularly to a turbidostat-enabled, robotics-assisted, high-throughput assisted evolution systems and methods for parallel, multi-pressure continuous evolution.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
4.
COMPOSITIONS FOR AND METHODS OF ENGINEERING THE TRANSCRIPTOME
Disclosed herein are CRISPR-free compositions for and methods of generating chimeric RNA molecules via trans-splicing and methods of treating and/or preventing a genetic disease or disorder (such as hypertrophic cardiomyopathy caused by one or more MYH7 mutations or aberrations) using chimeric RNA molecules generated via trans-splicing.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
5.
ELP FUSION OF BIOLOGICS AND METHODS OF MAKING AND USING THE SAME
Disclosed herein are fusion proteins comprising a biologic and an elastin‑like polypeptide (ELP) attached to the biologic that is capable of being expressed and secreted from a eukaryotic cell. Also disclosed herein are methods for producing the biologic-based fusion protein.
6.
METHODS FOR THE DIAGNOSIS AND TREATMENT OF PRECLINICAL ALZHEIMER'S DISEASE
The present invention provides methods and biomarkers useful for detecting, diagnosing and treating Alzheimer's Disease. The biomarkers for diagnoses may be used to develop treatment plans for subjects. The methods may be used to diagnose a subject prior to clinical onset of symptoms and may allow for early treatment which may slow progression of the disease.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
7.
129XE CHEMICAL SHIFT IMAGING, RECONSTRUCTION AND RBC CHEMICAL MAPS FOR IDENTIFYING CARDIOPULMONARY DISEASE
Methods and systems with acquired 129Xe CSI or DW-CSI undersampled voxels of a k-space during a breathhold MRI scan with reconstruction and quantification of RBC chemical shift values to provide a color scale RBC chemical shift map of a lung or lungs for evaluating disease states, use in drug discovery or monitoring disease status.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/485 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
8.
METASURFACE-ENHANCED PYROELECTRIC PHOTODETECTOR WITH SUB-NANOSECOND ELECTRICAL RESPONSE
A thermal photodetector is disclosed that converts incident electromagnetic radiation into an electrical signal with sub nanosecond response. The photodetector includes a pyroelectric layer, a continuous metallic layer in direct thermal and electrical communication with the pyroelectric layer, a dielectric spacer, and a metasurface of subwavelength metallic structures forming a nanogap cavity. Absorbed radiation is dissipated as heat primarily in the continuous metallic layer and transferred directly into the pyroelectric layer without an intervening thermal isolation structure. Device dimensions are selected such that an electrical RC time constant is less than 500 picoseconds, shifting the speed limitation from thermal diffusion to electrical response and enabling gigahertz bandwidth operation.
Disclosed herein are toughened polymer networks comprising organosilane and organogermanium crosslinkers, methods of making the same, and uses thereof.
C09D 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
Low-complexity detection of multiple uplink preambles in a wireless communication system subject to mobility and delay spread is described. A receiver receives a composite uplink signal including a superposition of transmissions from a plurality of user devices participating in a grant-free random access procedure. The composite uplink signal is processed to expose delay– and Doppler-related structure in a delay–Doppler representation that jointly resolves signal delay and frequency shift. In the delay–Doppler representation, features associated with respective uplink preambles transmitted by different user devices are identified, and the presence of multiple uplink preambles is determined based on the identified features. In some embodiments, detection is performed by selectively processing portions of the delay–Doppler representation based on expected delay and Doppler characteristics of the uplink preambles, such that computational complexity scales sublinearly with a size of the delay–Doppler representation.
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Disclosed herein are compositions and methods for the treatment of pain and/or related conditions. In particular, the disclosure provides methods and compositions for the treatment of pain, for example in complex regional pain syndrome, including administration of mesenchymal stem cells with high immunomodulatory potency.
A method for drug-target interactivity prediction. The method may include obtaining a quantized vector representation of a small molecule and obtaining a fixed-length representation of a protein. The method may further include applying a first attention transform to the quantized vector representation to generate a transformed quantized vector representation and applying a second attention transform to the fixed-length representation to generate a transformed fixed-length representation. The method may further include generating an inferred interactivity of the protein and the small molecule based on the transformed quantized vector representation and the transformed fixed-length representation.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
14.
METHODS FOR STABILIZING HENIPAVIRUS SURFACE GLYCOPROTEINS AND USES THEREOF
Described are structural identifications of the F and G proteins of a large variety Henipaviruses and their use in creating immunogens useful for vaccine compositions, and in prevention and treatment of Paramyxovirus and Henipavirus infections in a mammal. Also described are methods for screening viral fusion proteins for capability to transition from a pre-fusion to a post-fusion conformation. A monoclonal antibody specific for LayV-F is also provided.
Systems and methods are disclosed for supporting uplink communications in wireless networks operating under mobility and delay spread. A base station receives time-domain signals comprising preambles transmitted by multiple user equipments (UEs) within a random-access channel (RACH) slot and transforms the signals into a composite delay–Doppler (DD)-domain representation. The base station detects the preambles by correlating the DD-domain representation with reference pilot waveforms that are mutually unbiased with respect to corresponding UE waveforms, enabling discrimination of overlapping preambles under Doppler and multipath conditions. Uplink resource allocations, such as physical uplink shared-channel (PUSCH) occasions, are determined based on the detected preambles. In some embodiments, a UE generates mutually unbiased pilot and carrier waveforms in the DD domain, transforms them into time-domain signals, and transmits a pilot within a RACH slot to obtain uplink resources. The techniques support robust multi-user access and scheduling in high-mobility environments.
Disclosed herein are compositions and methods for increasing the activity, expression, or level of RELB. The compositions and methods may include a polynucleotide encoding RELB or a RELB polypeptide. The compositions and methods may further include a polynucleotide encoding RELA or a RELA polypeptide The compositions and methods may be used to increase proliferation of an exhausted tumor-infiltrating lymphocyte (TIL) or increase persistence in tumor killing in an exhausted TIL. The compositions and methods may be used to treat cancer.
17.
METHODS AND ASSAYS FOR SECRETOME ACTIVITY ANALYSIS
The present application provides methods and assays for assessing the effects of a mesenchymal stem cell secretome in order to use the MSC secretome in methods of treating ocular conditions and/disorders.
The present invention provides compositions comprising (a) a combination of influenza viral particles comprising a wild-type hemagglutinin (HA) protein and influenza viral particles comprising a headless HA protein, or (b) a combination of RNA molecules encoding a wild-type HA protein and RNA molecules encoding a headless HA protein. Vaccine formulations comprising these compositions and methods of using these compositions to induce an immune response in a subject are also provided.
The present invention provides methods for assessing longevity or overall health of a subject, and methods for assessing the efficacy of a therapeutic intervention in a subject. The methods comprise isolating extracellular vesicles from a subject and analyzing the extracellular vesicles to determine levels of a plurality of biomarkers. The biomarkers may be used to design personalized treatments and interventions and determine the effectiveness of such interventions.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
20.
ARTERIAL CANNULA DEVICE AND METHOD WITH PULSATILITY AND FLOW REVERSAL
The present disclosure describes, in part, arterial cannula systems for extracorporeal membrane oxygenation and cardiopulmonary bypass provides pulsatile blood flow and selective flow distribution. The cannula comprises a multi-lumen structure including a central lumen for blood flow, dedicated lumens for helium delivery, a distal orifice for body perfusion, and proximal orifices for limb perfusion. An inflatable cuff positioned between the distal and proximal orifices modulates blood flow through rapid inflation and deflation cycles achieved in milliseconds using helium gas. An external control console with microcontrollers and customized software automates the inflation-deflation cycles based on physiological inputs including ECG, arterial pressure, and tissue oxygenation. The system restores physiologically effective pulsatile flow, prevents limb ischemia, reduces thrombus formation risk, and can provide ECG-synchronized flow modulation to facilitate native cardiac ejection, potentially eliminating the need for separate left ventricular venting during mechanical circulatory support.
Disclosed herein are compositions for and methods of treating and/or slowing and/or reversing disease progression for one or more solute carrier (SLC) protein diseases.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. (Israel)
NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. (Israel)
DUKE UNIVERSITY (USA)
Inventor
Papo, Niv
Zalutsky, Michael R.
Abstract
The present invention is directed to a conjugate including: (i) an antigen-binding polypeptide having a specific binding affinity to prostate specific membrane antigen (PSMA); and (ii) a benzylguanidine prosthetic group including a radionuclide, wherein (i) and (ii) are covalently bound. Further provided are a composition including the conjugate, and use of same, such as in a theranostic method.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
A61P 35/04 - Antineoplastic agents specific for metastasis
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
C07C 279/12 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/60 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances involving radioactive labelled substances
23.
COMPOSITIONS COMPRISING ANTIBODIES HAVING PIGR-BINDING PEPTIDES AND METHODS OF USE THEREOF
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
24.
COMPOSITIONS FOR AND METHODS OF MODULATING TRANS-SPLICING EFFICIENCY
Disclosed herein are compositions for and methods of modulating RNA trans-splicing and methods of using disclosed compositions in methods treating and/or preventing a genetic disease or disorder with the mRNA generated via trans-splicing.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
25.
ELECTROPOLYMERS FOR CELL INTERFACE AND DEVICE AND METHODS THEREOF
Disclosed herein are electrically conductive polymer compositions comprising a polymer and a counter-ion, and methods of synthesizing the polymers therein. Also disclosed herein are microelectrode arrays comprising the electrically conductive material and a conductive polymer composition attached to a surface of the electrically conductive material. Further disclosed herein are methods of detecting electrical activity in a cell comprising contacting the microelectrode array with a cell and detecting electrical activity in the cell by covalently attaching the conductive polymer composition to a protein on the surface of the cell.
C08F 112/14 - Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing hetero atoms
C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances
Disclosed herein are methods, pharmaceutical compositions, and kits for image-guided brachytherapy. An example method includes navigating a hollow tube to a tumor in a subject using an imaging modality and administering a pharmaceutical composition through the hollow tube to the tumor. An example pharmaceutical composition includes a pharmaceutically acceptable excipient and a collection of self-assembling conjugates, each self-assembling conjugate including a radionuclide coupled to an elastin-like polypeptide, the collection of self-assembling conjugates being included in the pharmaceutical composition at a concentration of no more than 300 µM.
A61M 36/06 - Arrangements specially adapted for placing, e.g. inhaling or injecting, radioactive material within the body by fluid injection of radioactive or enhancing agent through a body-piercing conduit
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
27.
COMPOSITIONS AND METHODS FOR CARTILAGE REGENERATION AND/OR REPAIR
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
Inventor
Kraus, Virginia
Hsueh, Ming-Feng
Abstract
Provided herein are compositions, methods and biomarkers useful for detecting osteoarthritis and promoting and/or enhancing cartilage regeneration and/or repair in a subject suffering from osteoarthritis. The compositions include pro-anabolic RNAs or antisense oligonucleotides targeting (complementary to) anti-anabolic RNAs and combinations thereof. The compositions may include a nanocarrier or lipid nanoparticle. Also included are constructs encoding these RNAs or oligonucleotides.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
28.
METASURFACE ANTENNA SATELLITES AND METHODS THEREOF
A satellite antenna tile including an antenna layer oriented facing outward from the tile and configured to emit radio frequency (RF) signals, a structural support layer affixed to the antenna layer and comprising at least one mechanical support structure, and a power supply layer affixed to the structural support layer and comprising one or more power sources disposed on an opposite side of the tile from the antenna layer.
An antenna tile including a printed circuit board (PCB) layer comprising a plurality of radiating elements configured to transmit radio frequency (RF) signals, wherein a spacing between each pair of radiating elements is approximately one-half of a wavelength of the RF signals. A waveguide structure layer is affixed to the PCB layer to form a plurality of waveguide structures. A waveguide feed is coupled to the waveguide structure layer and configured to provide the RF signals to the PCB layer via the plurality of waveguide structures.
H01Q 3/44 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the electric or magnetic characteristics of reflecting, refracting, or diffracting devices associated with the radiating element
H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
In one or more embodiments, the present invention provides a system for local drug delivery using electrospun poly(ester urea) nanofibers to rapidly deliver local pain killers, NSAIDs and/or other local analgesics to injury sites. These drug-loaded poly(ester urea) (PEU) nanofibers provides acute pain relief, preserves patient mobility, and reduces risk of central sensitization. These drug-loaded poly(ester urea) (PEU) nanofibers are made using a bicarbonate as an additive during the electrospinning process, thereby increasing the porosity, and with it the surface-to-volume ratio, of the spun fibers nanofibers. It has been found, unexpectedly, that use of the sodium bicarbonate additive can double or even triple the amount of the drug that can be delivered. Further, by controlling the molecular weight of the PEU polymer, the diameter of the nanofibers, and the type and/or amount of additive being used, the drug release kinetics can be tuned.
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
A nanoparticle vaccine composition includes a shell including one or more amphiphilic molecules and one or more hapten molecules, where at least one amphiphilic molecule is conjugated to the hapten molecule, and a substantially hydrophobic core including an immunogenic protein, a vaccine adjuvant, one or more inert biocompatible materials, or a combination of two or more thereof, where the core is encapsulated in the shell to form a nanoparticle.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
34.
SYSTEM AND METHOD FOR PREDICTING PULMONARY COMPLICATIONS FOLLOWING RIB FRACTURES
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (USA)
DUKE UNIVERSITY (USA)
Inventor
Fernandez-Moure, Joseph
Elster, Eric A.
Schobel-Mchugh, Seth A.
Grey, Scott F.
Li, Renhua
Abstract
Described herein are methods, systems, and computational environments for predicting clinical outcomes based on a regression model trained on data of patients having a rib fracture. Also described are methods, systems, and computational environments for generating the regression model for predicting clinical outcomes. One aspect of the present disclosure provides a method of determining a subject's risk of adverse response after a rib fracture, comprising, consisting of, or consisting essentially of applying a predictive algorithm to serum analysis data including one or more biomarkers.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The present disclosure provides systems and methods relating to brain stimulation therapy. In particular, the present disclosure provides systems and methods for identifying effective stimulation patterns for reducing one or more symptoms or a neurological or psychiatric disorder.
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08J 5/00 - Manufacture of articles or shaped materials containing macromolecular substances
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
37.
SYSTEM AND METHOD FOR LOW INTENSITY FOCUSED ULTRASOUND BRAIN STIMULATION
A system and method for treating a patient with stroke-related deficiencies. The treatment includes modulating discrete cortical or deep sub-cortical regions of the patient's brain. The modulation is provided by low-intensity focused ultrasound (LIFU) as it can be configured to be selective, targeted, reversible, and non-invasive with millimeter precision across the entire human brain.
Described herein is a computer-implemented method for training a machine learning model for predicting one or more physiochemical properties of a nanoparticle. In some instances, the method includes receiving a set of data including nanoparticles, generating a descriptor and fingerprint for each nanoparticle in the set of data, creating a plurality of sets of training data and a plurality of sets of test data, training a machine learning model of an artificial intelligence (AI) system using the plurality of sets of training data, and predicting a property of the drug-excipient pair of the plurality of sets of test data based on drug-excipient pairs and property values of each drug-excipient pair of the plurality of sets of training data. Also described herein are excipients conjugated to a polyethylene glycol moiety, or pharmaceutically acceptable salts thereof. In some instances, the excipients may be used to form nanoparticles with a therapeutic compound.
The present invention provides compositions comprising one or more polynucleotides that encode a neuraminidase (NA) polypeptide and a hemagglutinin (HA) polypeptide separated by a furin cleavage site and a self-cleaving 2A polypeptide. Methods of using these compositions to induce an immune response to influenza in a subject are also provided.
Disclosed herein are microfluidic assay devices that have improved versatility and reliability. An example microfluidic assay device includes a cassette having a body formed by a plurality of layers. The body includes a reaction chamber having an inlet, an outlet downstream from the inlet, and a non-fouling polymer brush with a plurality of assay reagents. The reaction chamber is configured to house a fluid sample. The body also includes a seal disposed adjacent the outlet of the reaction chamber for preventing fluid flow through the outlet, and an actuator configured to break the seal upon actuation to create a fluid flow path for the fluid sample to exit from the outlet of the reaction chamber.
The present disclosure provides systems and methods relating to the neuromodulation of gastrointestinal dysmotility. In particular, the present disclosure provides systems and methods for delivering temporal patterns of electrical stimulation comprising burst-patterned stimulation according to various stimulation parameters to treat gastrointestinal dysmotility disorders in a subject. The system may be implantable.
A method of cavitation mapping in a region of interest is provided. Methods, systems and computer program products according to some embodiments include receiving ultrasound signals from a cavitation event with an ultrasound array; and localizing the cavitation event to determine a cavitation location. The method also includes mapping the cavitation location on an image; and providing information characterizing the cavitation event.
A method of determining mechanical properties of a sample using thermorheological data includes providing a sample in a dynamic mechanical analysis device; selecting a temperature for the sample; performing a high-bandwidth time/frequency/temperature sweep test comprising: applying a broadband mechanical impulse over a frequency range at the temperature, and collecting thermorheological data during application of the broadband mechanical impulse; and determining mechanical properties of the sample using the thermorheological data, and, optionally, generating a viscoelastic master curve.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The invention is directed to modified recombinant HIV-1 envelopes comprising one or more modified recombinant HIV-1 fusion proteins, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.
Methods for treating cancer in a subject in need thereof by administration of a compound of Formula (I) are described herein. The methods may treat cancer by degrading heat shock factor 1 (HSF1), arresting tumor growth, treatment of malignant bone marrow, the selective killing of malignant bone marrow, etc.
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
50.
COMPOSITIONS COMPRISING SCFV SEQUENCES TARGETING CANCER ANTIGENS AND METHODS OF USE THEREOF
Disclosed herein are CARs targeting TAS2R13, TMEM191C, ADAM20, or any combination thereof on the surface of cancer cells. Also disclosed are compositions comprising CARs targeting TAS2R13, TMEM191C, ADAM20, or any combination thereof and methods of using these compositions to treat cancer and/or slowing disease progression in a subject.
Disclosed herein are antibodies, antibody drug conjugates, and bispecific T cell engagers targeting TAS2R13, TMEM191C, ADAM20, or any combination thereof on the surface of cancer cells. Also disclosed are methods of using these compositions to treat cancer and/or slowing disease progression in a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides, in part, combination therapies and methods of eliciting immuno-tolerance using PDL1 variants and immune system modulators.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, treatment, and identification of the presence of pretangles in a subject. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
54.
HIV-1 ENV IMMUNOGENS THAT TARGET UCAS AGAINST MULTIPLE ANTIGENIC SITES
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
A method is described herein comprising training a protein language model using a first dataset to predict neutralization values of individual antibody sequences against corresponding Env sequences, using the trained model on a second dataset to identify neutralizing values of individual antibody sequences in the second dataset against Env sequences in a virus panel, summing the identified neutralization values of antibodies in the second dataset to identify a first set of broadly neutralizing antibody (bnAb) precursors, wherein an antibody sequence qualifies as a precursor when its summed neutralization values exceed a threshold, structurally comparing the first set of bnAb precursors to a known bnAb, using information of the structural comparison to identify a second set of bnAb precursors, maturing the second set of precursors to breadth, and identifying immunogens that select for the matured precursors.
Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.
C08H 1/00 - Macromolecular products derived from proteins
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Fernandez-Moure, Joseph S.
Peloquin, Jacob
Abstract
A system for minimally invasive rib fixation including a plate for fixating a rib. The plate has a plate boss extending from a surface of the plate. The system further includes a shield having a collar releasably coupled to the plate boss such that the shield is oriented perpendicular to the plate and an engagement portion integrally formed with the collar. The engagement portion is configured to engage a screw being driven into the plate and to flex for uncoupling the shield from the plate boss.
Disclosed are systems and methods for training a risk stratification model for estimating patient risk levels. Weights are extracted from a source model, the weights defining a relationship between patient data and patient risk level. The weights are used to calculated a score for each patient in a target population, and the source model is then refitted to the target population, using a transfer learning estimator based on the calculated scores. The refitted source model can then be outputted for use.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
59.
USE OF IL-2 VARIANT FOR TREATING KIDNEY TRANSPLANT REJECTION
The present invention provides, among other things, a. method of prophylaxis for kidney rejection comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplant. In another aspect, the present invention provides, among other things, a method of improving a kidney transplant in a recipient, comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplantation at a therapeutically effective amount, wherein the improvement in the kidney transplant results in prolonged stability of the kidney transplant, survival of the recipient, and/or reduced rejection symptoms as compared to a control.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
60.
METHODS AND COMPOSITIONS RELATING TO ECDNA BIOGENESIS
Described herein are systems, compositions, methods, and kits relating to the study and inhibition of ecDNA formation. Described herein are reporter systems useful for identifying intracellular molecular regulators of ecDNA formation. Described herein are reporter systems that are useful as screens for identifying inhibitors of ecDNA formation. Also described herein are methods relating to further identifying molecular mechanisms of ecDNA biogenesis. Also described herein are methods of treating a disease in a subject by an administering an agent that inhibits ecDNA formation.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
Disclosed herein are methods and recombinant partially ordered polypeptides for repairing nerve injuries, such as a peripheral nerve injury. The methods and polypeptides can take advantage of temperature-dependent phase transition behavior of the polypeptide to provide biocompatible, porous scaffolds for beneficial outcomes in nerve repair. An example method includes administering a recombinant partially ordered polypeptide to a location of a nerve injury in a subject. An example recombinant partially ordered polypeptide includes a plurality of disordered domains, a plurality of structured domains, and an optional neuroregenerative domain.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
63.
INTEGRATED PULSE OPTIMIZER AND SIMULATOR FOR HIGH-FIDELITY TWO-QUBIT GATES ON TRAPPED IONS
Technologies for simulating and optimizing electromagnetic pulses are disclosed herein. A quantum computing system generates, based on a specification of one or more system parameters, one or more control values, and one or more noise offsets, a controlled environment for a quantum computing system. The quantum computing system simulates, as a function of the control values, one or more pulses within the controlled environment. One or more candidate pulses are identified based on an evaluation of the simulated pulses. A sequence comprising properties of at least one of the candidate pulses is returned.
The present invention provides NKG2D fusion proteins comprising a domain of NKG2D and a scFv specific for CDS and methods of making and using the same. The fusion proteins provided herein may be administered in combination with CAR T cells. In addition, CAR T cells or other immune cells engineered to express the NKG2D fusion proteins described herein are also provided and may be used in the methods described herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
Described herein are biomimetic microfluidic devices comprising electrospun silk fibroin membranes. In some embodiments, the biomimetic microfluidic device is a kidney glomerulus organ-on-chip device. Also described herein are methods of filtering a sample, methods of screening an agent for treatment of a kidney or glomerular disorder, and methods of generating fenestrated endothelial cells using the biomimetic microfluidic devices described herein.
A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
D01D 5/00 - Formation of filaments, threads, or the like
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
A method optimizes operating room scheduling under uncertainty by: receiving a set of prospective activities to be scheduled, said prospective activities relating to operating room surgeries that consume healthcare resources for a duration of time; generating a set of mathematical distributions associated with a collection of prospective activity types, where a prospective activity type can be defined in terms of the surgery code, the surgeon ID, and other attributes, wherein each mathematical distribution quantifies the uncertainty with regard to the time duration for the retrospective prospective activity type and is constructed using stored historical data relating to the operating room surgeries; and constructing at least one schedule for the prospective activities that optimizes the utilization of healthcare resources within a defined set of constraints using the mathematical distributions such that the at least one schedule incorporates the quantified uncertainty. The method can adapt to new historical data and operational constraints.
Disclosed herein are adeno-associated virus (AAV) vectors comprising capsid protein variants, for example that have tropism for human T-cells. Also disclosed herein are pharmaceutical compositions comprising these AAV vectors and capsid protein variants as well as methods of making such vectors and capsid protein variants. Disclosed herein are methods of using the disclosed AAV vectors and disclosed capsid protein variants.
G01N 31/12 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using combustion
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C12N 15/62 - DNA sequences coding for fusion proteins
71.
COMPOSITIONS FOR AND METHODS OF ENGINEERING THE TRANSCRIPTOME
Disclosed herein are compositions for and methods of generating chimeric RNA molecules via trans-splicing and methods for determining the efficacy of guide RNA and RNA targeting motifs in trans-splicing processes including, for example, SMaRT, CRAFT, and GRAFT.
Disclosed herein are variant membrane-associated accessory proteins (MAAPs) and methods of using variant MAAP variants to generate AAV particles and improve AAV secretion and/or AAV egress.
Embodiments are directed to a conjugate peptide including a self-assembling peptide and at least one allergen epitope. Allergen epitopes may include peanut allergens. The conjugate peptide may self-assemble into a nanofiber or fibril. Compositions including the conjugate peptide may be used to treat allergies.
Disclosed herein are mechanoenhancers and compositions and methods for modulating expression of a mechanoenhancer. Modulation of the mechanoenhancer may result in apoptosis, mechanotransduction, proliferation, migration, or growth, or a combination thereof. The compositions and methods may be used to treat disease such as cancer or fibrosis.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
75.
COMPOSITIONS COMPRISING SELECTIVE CELL IN ORGAN TARGETING AND METHODS OF USING THE SAME
Disclosed herein are compositions comprising LNPs capable of selectively targeting cancer cells in organs for the efficient delivery of RNA cargos, specifically aimed at targeting poorly druggable, disease-driving transcription factors in prostate cancer and methods of use thereof.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Cylindrical motion control for an additive manufacturing system includes a cylindrical printing attachment. The cylindrical printing attachment can include a body having a platen-contacting surface for coupling to a platen of the additive manufacturing system, a rack surface, and an axle clamp track; a rack and pinion gear assembly, including a rack and a pinion, wherein the pinion rotatably engages with the rack, wherein the rack is coupled to the rack surface of the body; and an axle clamp structured to rotate along the axle clamp track of the body as the pinion rotates along the rack.
A radio frequency applicator, including a waveguide having a first interior surface comprising a first aperture, a second interior surface opposing the first interior surface, a third interior surface adjacent to the first and second interior surfaces, a fourth interior surface opposing the third interior surface, and a fifth interior surface perpendicular to the first, second, third, and fourth interior surfaces, an aperture antenna, a solid dielectric insert within the waveguide, the solid dielectric insert having a second aperture formed therethrough that is configured for alignment with the first aperture, an RF connector, configured to receive generated RF energy pulses, at least one planar-shaped shim, having a third aperture therethrough configured to align with the first and second apertures, and a radio frequency feed pin connected to the RF connector, disposed within the first, second, and third apertures and affixed to the second interior surface of the waveguide.
Disclosed herein are chimeric antigen receptors targeting cVIM on the surface of cancer cells. Also disclosed are compositions comprising CARs targeting cVIM and methods of using these compositions to treat cancer and/or slowing disease progression in a subject.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed are coronavirus-based immunogens, including immunogens comprising receptor binding domain (RBD), comprised in immunogen displays (e.g., nanoparticles). Provided also are immunogenic compositions and methods of using the compositions to induce immunogenic responses in a subject.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ PARIS CITÉ (France)
DUKE UNIVERSITY (USA)
UNIVERSITÉ DE MONTPELLIER (France)
ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE MONTPELLIER (France)
Inventor
Puissant, Alexandre
Wood, Kris
Martin, Anthony
Abstract
γγ-PIK3R5/p101 axis blocks AKT signaling, compromises cell fitness, and sensitizes to established AML therapies. Importantly, the inventors find that existing small molecule inhibitors against PIK3CG are insufficient to achieve a sustained longterm anti-leukemic effect. To address this concern, the inventors developed a proteolysis- targeting chimera (PROTAC) heterobifunctional molecule that specifically degrades PIK3CG and potently suppresses AML progression alone and in combination with venetoclax in human AML cell lines, primary AML patient samples, and syngeneic mouse models.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
ditert22 catalyst. These resins may also include at least one suitable photoinitiator and, optionally, a light attenuating agent or photoinhibitor. Advantageously, it has been reported that these resins have a complex viscosity that is suitable for 3D printing (from about 0.5 Pa·s to about 20.0 Pa·s) at room temperature without the need for a solvent or other diluent.
Disclosed herein are methods for treating or reducing symptoms of a neurodegenerative disease in a subject. This disclosure relates to a method of restoring the tertiary structure of a mutant C terminus of HSP70-Interacting Protein (CHIP) to the tertiary structure of wild-type CHIP. Also disclosed herein are methods of increasing ubiquitination of a protein by a mutant C terminus of HSP70-Interacting Protein (CHIP) and methods of treating a neurodegenerative disorder comprising administering a therapeutically effective amount of a small molecule or a peptide to a subject.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A sono-ink composition is described that includes a acrylate oligomer, an acoustic absorber, and a thermal initiator. A method of using the sono-ink for deep-penetrating volumetric printing is also described. The method includes the steps of a) providing a volume of a sono-ink composition, comprising a acrylate oligomer, an acoustic absorber, and a thermal initiator; b) directing a focused acoustic projection of ultrasound waves into the volume of the sono-ink, wherein the focused acoustic projection of ultrasound waves has an intensity and frequency sufficient to activate the thermal initiator so that local polymerization is achieved at a desired region within the volume of sono-ink; and c) optionally repeating step b wherein the focused acoustic projection of ultrasound waves is directed to selected regions within the sono-ink, until a three-dimensional object is formed.
B29C 35/02 - Heating or curing, e.g. crosslinking or vulcanising
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
B29C 64/165 - Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
B33Y 80/00 - Products made by additive manufacturing
C08F 2/56 - Polymerisation initiated by wave energy or particle radiation by ultrasonic vibrations
C08F 265/06 - Polymerisation of acrylate or methacrylate esters on to polymers thereof
C08H 1/00 - Macromolecular products derived from proteins
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
84.
IMPROVED TYROSINE HYDROXYLASE PROMOTERS AND NUCLEIC ACID COMPOSITIONS AND USES THEREOF
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
85.
SYSTEMS, DEVICES, AND METHODS FOR DIFFRACTIVE PHOTOACOUSTIC AND ULTRASOUND IMAGING
Systems and methods for producing a three-dimensional diffractive acoustic tomography system are disclosed herein. Such systems are configured to enable the imaging of microvasculature and functional dynamics of tissue samples with a broad field of view and high spatial resolution. According to several disclosed embodiments, a combination of ultrasonic and photoacoustic imaging combined emitted and received through a slit enables rapid imaging of target materials.
Disclosed are coronavirus-based immunogens, including immunogens comprising spike protein and or domains thereof, comprised in immunogen displays (e.g., nanoparticles). Provided are also immunogenic compositions and methods of using these immunogens to induce immunogenic responses in a subject.
Provided herein are methods and biomarkers useful for detecting and diagnosing osteoarthritis and its severity and predicting the progression of osteoarthritis in subjects. The biomarkers for diagnoses and prognoses may be used to develop treatment plans for subjects.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
88.
BLOCK COPOLYMER NANOPARTICLES FOR SUSTAINED DRUG DELIVERY
Disclosed herein are POEGMA-based block copolymers that have phase transition and self-assembly properties. The disclosed block copolymers can take advantage of these properties to form particles that can effectively encapsulate and deliver drugs. An example block copolymer includes a first block that includes POEGMA with ethylene glycol side chains of 2 monomers, 3 monomers, or combinations of both; and a second block that includes POEGMA with ethylene glycol side chains of 1 monomer, 2 monomers, or combinations of both. Also disclosed herein are compositions that include the block copolymers, methods of treating a disease or disorder, and methods of delivering a drug.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
90.
MEMBRANE PROXIMAL EXTERNAL REGION (MPER) FROM HIV THAT STIMULATES BROADLY NEUTRALIZING ANTIBODIES (BNABS)
Disclosed are membrane proximal external region (MPER) immunogens from HIV that can stimulate broadly neutralizing antibodies (bnABS), lipid immunogen displays having the MPER immunogens, and methods for stimulating antibodies using the MPER immunogens and lipid immunogen displays.
Disclosed are recombinant proteins encoding HIV-1 fusion peptides and configured for incorporation into an immunogen display (e.g., self-assembling protein nanoparticle). Disclosed are the immunogen displays and methods of using the immunogen displays to stimulate an immune response in a subject.
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
The present disclosure provides a gene delivery system in which transgenic mitochondria are administered to an animal to permit expression of the transgene and secretion of a transgene- encoded protein to an animal.
Disclosed herein are compositions comprising nanoparticles designed for CRISPR/Cas13 RNA targeting systems, specifically aimed at targeting poorly druggable, disease-driving genes in prostate cancer and COVID-19, and methods of use thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from TGIF2LX, TGIF1, TGIF2, FOS, HNF4A, KLF8, NFKBIZ, CARF, EBF3, HMX3, LHX4, LMX1A, PLAG1, PLAGL1, POU2F3, SOX14, TFAP2D, and WT1, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
The disclosure provides methods of treating cancer, such as an estrogen receptor negative (ER–) solid cancer or estrogen receptor-low (ERlow) solid cancer in a patient. The method may include administering to the patient an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed herein are functionalized branched poly-lysine compounds and uses thereof, as well as delivery systems in which polymeric nanocarriers are functionalized with branched poly-lysine compounds. Also provided herein are uses of the functionalized branched poly-lysine compounds and the delivery systems for treating joint diseases such as osteoarthritis, and in delivering pharmaceutically active compounds to cartilage and subchondral bone.
C08G 69/48 - Polymers modified by chemical after-treatment
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from THAP6, DMRT3, MEF2B, PAX2, ATOH7, KLF2, KLF1, TWIST1, NKX6, and FEV, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Genome sequencing identified a new gene associated with a cardiac arrhythmic disease, TAXI -binding protein 3. From cell line models and a conditional knock-out mouse models of the gene deletion, it was found that a specific molecule, transient receptor potential vanilloid 4 (TRPV4), is up-regulated and is associated with calcium mediated arrhythmic depolarizations.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
100.
SUMOYLATION AS A THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES AND INFECTIONS DISORDERS
The present disclosure provides methods of treating or preventing inflammatory bowel disease or sepsis in a subject by inhibiting SUMOylation in the subject.
patents
